10/31/14 NUVA 40.90 Nuvasive Inc $NUVA Hit a 52 we
Post# of 51
Posted On: 11/02/2014 1:53:18 AM
10/31/14 NUVA 40.90 Nuvasive Inc $NUVA Hit a 52 week high of 42.44 Closing the day 10/31/14 at 40.90 +1.64 +4.18% With a day low of 40.00 and a total volume of 921,100.
NUVA Recent Posts: http://investorshangout.com/NuVasive-Inc-NUVA-54931/
NUVA Nuvasive Inc Recent Headline News
NuVasive Reports Third Quarter 2014 Financial Results and Increases Full Year Guidance
Marketwired - Thu Oct 30, 3:07PM CDT
NuVasive, Inc. (NASDAQ: NUVA)
NUVA: 40.90 (+1.64)
NuVasive Announces Conference Call and Webcast of Third Quarter 2014 Results
Marketwired - Thu Oct 16, 3:30PM CDT
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that its third quarter 2014 earnings announcement will take place on Thursday, October 30, 2014, after the close of the market.
NUVA: 40.90 (+1.64)
Insider Trading Alert - REX, NVAX And NUVA Traded By Insiders
at The Street - Tue Oct 07, 10:54AM CDT
Stocks with insider trader activity include REX, NVAX and NUVA
NVAX: 5.60 (-0.03), REX: 72.76 (+2.46), NUVA: 40.90 (+1.64)
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innovative Product Exhibition
Thomson Reuters ONE - Wed Oct 01, 7:31AM CDT
Product Demonstrations and Spine Procedure Workshops Highlight Commitment to Serving the Needs of Patients and Surgeons in Europe; Company Also Announces Opening of New European Center of Excellence in Amsterdam
NUVA: 40.90 (+1.64)
Will This Analyst Upgrade Help NuVasive (NUVA) Stock Today?
at The Street - Tue Sep 30, 8:31AM CDT
Brean Capital upgraded NuVasive (NUVA) to 'buy' from 'hold' and set a $44 price target.
NUVA: 40.90 (+1.64)
Upgrade Alert for NuVasive (NUVA)
Comtex SmarTrend(R) - Tue Sep 30, 7:07AM CDT
NuVasive (NASDAQ:NUVA) was upgraded from Hold to Buy at Brean Capital today. The stock closed yesterday at $35.02 on volume of 139,000 shares, below average daily volume of 256,000. NuVasive, Inc. designs, develops, and markets products for the surgical treatment of spine disorders. The Company's products include Maximum Access Surgery (MAS) and Fusion products.
NUVA: 40.90 (+1.64)
St. Jude Medical Gets Award for Leadless Pacemaker Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 12:50PM CDT
In June this year, St. Jude Medical (STJ) had received the 2014 Innovation Award at Cardiostim 2014 ??? the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques ??? for its Nanostim leadless pacemaker.
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), STJ: 64.17 (-0.11), NUVA: 40.90 (+1.64)
Is Abaxis (ABAX) a Buy After Solid Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:50PM CDT
On Sep 5, 2014, we issued an updated research report on Abaxis Inc. (ABAX).
MWIV: 169.65 (+3.85), ABAX: 52.66 (+1.13), EGRX: 12.67 (-0.13), NUVA: 40.90 (+1.64)
Symmetry Medical Updates on OEM Solutions Divestment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 12:40PM CDT
According to Symmetry Medical (SMA), the proposed sale will recognize the value of the OEM Solutions business and enhance the growth potential of Symmetry Surgical.
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), ABAX: 52.66 (+1.13), NUVA: 40.90 (+1.64)
NuVasive Spine Foundation(TM) Exceeds $13 Million in Global Effort to Support Patients in Need
Marketwire - Mon Sep 08, 9:37AM CDT
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is proud to announce today that the NuVasive Spine Foundation(TM) (NSF), a non-profit organization founded and managed by NuVasive, has reached a cumulative milestone of more than $13 million contributed since the Foundation's inception in 2009. To date, NuVasive has donated approximately $10.5 million in surgical products. The announcement follows the successful completion of the Seventh Annual NuVasive Spine Foundation San Diego Golf Tournament held at the Maderas Golf Club on August 24, 2014.
NUVA: 40.90 (+1.64)
Insider Trading Alert - REX, PSEC And NUVA Traded By Insiders
at The Street - Thu Sep 04, 9:05AM CDT
Stocks with insider trader activity include REX, PSEC and NUVA
REX: 72.76 (+2.46), NUVA: 40.90 (+1.64), PSEC: 9.58 (-0.05)
Baxter Expects to Grow on Acquisitions and Product Lineups - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:10PM CDT
Baxter International (BAX) operates in the life-sustaining and critical care products category that should remain relatively insulated from economic downturns.
ICUI: 70.90 (unch), BAX: 70.14 (+0.08), NEOG: 43.90 (-0.14), NUVA: 40.90 (+1.64)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
ResMed Continues to Disappoint despite OSA Market Potential - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 3:45PM CDT
On Aug 25, 2014, we issued an updated research report on ResMed, Inc. (RMD).
ICUI: 70.90 (unch), ABAX: 52.66 (+1.13), RMD: 52.22 (+0.11), NUVA: 40.90 (+1.64)
Symmetry Medical Shows Stability on Bottom Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 1:50PM CDT
Symmetry Medical's (SMA) divestment of its U.K. based subsidiary, Clamonta Ltd. on May 22, 2014 was also in sync with its plans to focus on its core markets and reduce its manufacturing footprint
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), ABAX: 52.66 (+1.13), NUVA: 40.90 (+1.64)
Earnings Look Back: NuVasive Is Up 1.3% Since Reporting Quarterly Results 2 Weeks Ago (NUVA)
Comtex SmarTrend(R) - Mon Aug 18, 9:05AM CDT
When NuVasive (NASDAQ:NUVA) reported earnings two weeks ago on July 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $177.4 million. NuVasive actually reported earnings of $0.28 per share on sales of $190.7 million, beating EPS estimates by $0.03 and beating revenue estimates by $13.3 million. Shares of NuVasive have climbed from $35.06 to $35.52, representing a gain of 1.3% since the company reported earnings 20 days ago.
NUVA: 40.90 (+1.64)
NUVA Recent Posts: http://investorshangout.com/NuVasive-Inc-NUVA-54931/
NUVA Nuvasive Inc Recent Headline News
NuVasive Reports Third Quarter 2014 Financial Results and Increases Full Year Guidance
Marketwired - Thu Oct 30, 3:07PM CDT
NuVasive, Inc. (NASDAQ: NUVA)
NUVA: 40.90 (+1.64)
NuVasive Announces Conference Call and Webcast of Third Quarter 2014 Results
Marketwired - Thu Oct 16, 3:30PM CDT
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that its third quarter 2014 earnings announcement will take place on Thursday, October 30, 2014, after the close of the market.
NUVA: 40.90 (+1.64)
Insider Trading Alert - REX, NVAX And NUVA Traded By Insiders
at The Street - Tue Oct 07, 10:54AM CDT
Stocks with insider trader activity include REX, NVAX and NUVA
NVAX: 5.60 (-0.03), REX: 72.76 (+2.46), NUVA: 40.90 (+1.64)
NuVasive(R) Demonstrates Expanding EMEA Business at Eurospine 2014 With Surgeon Workshops and Innovative Product Exhibition
Thomson Reuters ONE - Wed Oct 01, 7:31AM CDT
Product Demonstrations and Spine Procedure Workshops Highlight Commitment to Serving the Needs of Patients and Surgeons in Europe; Company Also Announces Opening of New European Center of Excellence in Amsterdam
NUVA: 40.90 (+1.64)
Will This Analyst Upgrade Help NuVasive (NUVA) Stock Today?
at The Street - Tue Sep 30, 8:31AM CDT
Brean Capital upgraded NuVasive (NUVA) to 'buy' from 'hold' and set a $44 price target.
NUVA: 40.90 (+1.64)
Upgrade Alert for NuVasive (NUVA)
Comtex SmarTrend(R) - Tue Sep 30, 7:07AM CDT
NuVasive (NASDAQ:NUVA) was upgraded from Hold to Buy at Brean Capital today. The stock closed yesterday at $35.02 on volume of 139,000 shares, below average daily volume of 256,000. NuVasive, Inc. designs, develops, and markets products for the surgical treatment of spine disorders. The Company's products include Maximum Access Surgery (MAS) and Fusion products.
NUVA: 40.90 (+1.64)
St. Jude Medical Gets Award for Leadless Pacemaker Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 12:50PM CDT
In June this year, St. Jude Medical (STJ) had received the 2014 Innovation Award at Cardiostim 2014 ??? the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques ??? for its Nanostim leadless pacemaker.
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), STJ: 64.17 (-0.11), NUVA: 40.90 (+1.64)
Is Abaxis (ABAX) a Buy After Solid Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:50PM CDT
On Sep 5, 2014, we issued an updated research report on Abaxis Inc. (ABAX).
MWIV: 169.65 (+3.85), ABAX: 52.66 (+1.13), EGRX: 12.67 (-0.13), NUVA: 40.90 (+1.64)
Symmetry Medical Updates on OEM Solutions Divestment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 12:40PM CDT
According to Symmetry Medical (SMA), the proposed sale will recognize the value of the OEM Solutions business and enhance the growth potential of Symmetry Surgical.
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), ABAX: 52.66 (+1.13), NUVA: 40.90 (+1.64)
NuVasive Spine Foundation(TM) Exceeds $13 Million in Global Effort to Support Patients in Need
Marketwire - Mon Sep 08, 9:37AM CDT
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is proud to announce today that the NuVasive Spine Foundation(TM) (NSF), a non-profit organization founded and managed by NuVasive, has reached a cumulative milestone of more than $13 million contributed since the Foundation's inception in 2009. To date, NuVasive has donated approximately $10.5 million in surgical products. The announcement follows the successful completion of the Seventh Annual NuVasive Spine Foundation San Diego Golf Tournament held at the Maderas Golf Club on August 24, 2014.
NUVA: 40.90 (+1.64)
Insider Trading Alert - REX, PSEC And NUVA Traded By Insiders
at The Street - Thu Sep 04, 9:05AM CDT
Stocks with insider trader activity include REX, PSEC and NUVA
REX: 72.76 (+2.46), NUVA: 40.90 (+1.64), PSEC: 9.58 (-0.05)
Baxter Expects to Grow on Acquisitions and Product Lineups - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:10PM CDT
Baxter International (BAX) operates in the life-sustaining and critical care products category that should remain relatively insulated from economic downturns.
ICUI: 70.90 (unch), BAX: 70.14 (+0.08), NEOG: 43.90 (-0.14), NUVA: 40.90 (+1.64)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
ResMed Continues to Disappoint despite OSA Market Potential - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 3:45PM CDT
On Aug 25, 2014, we issued an updated research report on ResMed, Inc. (RMD).
ICUI: 70.90 (unch), ABAX: 52.66 (+1.13), RMD: 52.22 (+0.11), NUVA: 40.90 (+1.64)
Symmetry Medical Shows Stability on Bottom Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 1:50PM CDT
Symmetry Medical's (SMA) divestment of its U.K. based subsidiary, Clamonta Ltd. on May 22, 2014 was also in sync with its plans to focus on its core markets and reduce its manufacturing footprint
ICUI: 70.90 (unch), SMA: 9.90 (+0.16), ABAX: 52.66 (+1.13), NUVA: 40.90 (+1.64)
Earnings Look Back: NuVasive Is Up 1.3% Since Reporting Quarterly Results 2 Weeks Ago (NUVA)
Comtex SmarTrend(R) - Mon Aug 18, 9:05AM CDT
When NuVasive (NASDAQ:NUVA) reported earnings two weeks ago on July 29th, 2014, analysts, on average, expected the company to report earnings of $0.25 on sales of $177.4 million. NuVasive actually reported earnings of $0.28 per share on sales of $190.7 million, beating EPS estimates by $0.03 and beating revenue estimates by $13.3 million. Shares of NuVasive have climbed from $35.06 to $35.52, representing a gain of 1.3% since the company reported earnings 20 days ago.
NUVA: 40.90 (+1.64)
(0)
(0)